Listar por tema "Gastrointestinal Agents/therapeutic use"

Mostrando ítems 1-5 de 5

Biosimilar infliximab CPT-13 for inflammatory bowel disease in a real clinical setting: pharmacokinetic outcomes, immunogenicity, and drug survival

Iniesta-Navalón, Carles; Gil-Candel, Mayte; Salar-Valverde, Ignacio; Nicolás-de-Prado, Isabel; Gómez-Espín, Rosa; Rentero-Redondo, Lorena (Arán Ediciones, 2021)

BACKGROUND: efficacy and safety were evaluated after switching to a biosimilar infliximab (CPT-13) in patients with inflammatory bowel disease (IBD). However, few cohort studies compare the pharmacokinetic profiles, ...
Impact of proactive therapeutic drug monitoring of infliximab during the induction phase in IBD patients. A Bayesian approach

Serrano-Díaz, Lidia; Iniesta-Navalón, Carles; Gómez-Espín, Rosa; Nicolás-de-Prado, Isabel; Bernal-Morell, Enrique; Rentero-Redondo, Lorena (ARAN Ediciones S.L, 2023)

BACKGROUND AND OBJECTIVES: there is increasing evidence that proactive therapeutic drug monitoring in induction is useful to improve the control of inflammatory bowel disease (IBD), although it remains controversial. The ...
Regression of a giant pseudopolyp in a patient with colonic Crohn's disease after therapy with infliximab

Sánchez, José-Francisco; Navarro, Belén; Rubio, José-María; Bastida, Guillermo; Nos, Pilar (ARAN EDICIONES, S A, 2019)

Giant inflammatory pseudopolyps (> 15 mm) are an uncommon complication of inflammatory bowel disease (IBD) and a differential diagnosis with adenomas and carcinomas is challenging. Although usually asymptomatic, they may ...
Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients

Gil-Candel, Mayte; Gascón-Cánovas, Juan-José; Gómez-Espín, Rosa; Nicolás-de-Prado, Isabel; Rentero-Redondo, Lorena; Urbieta-Sanz, Elena; Iniesta-Navalón, Carles (Arán Ediciones, 2020)

INTRODUCTION: infliximab is used in inflammatory bowel disease, which has a great inter-individual pharmacokinetic variability. Thus, it is necessary to individualize the therapy in many cases. The main objective of our ...
Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease

Gil-Candel, Mayte; Gascón-Cánovas, Juan-José; Urbieta-Sanz, Elena; Gómez-Espín, Rosa; Nicolás-de-Prado, Isabel; Iniesta-Navalón, Carles (Arán Ediciones, 2020)

INTRODUCTION: previous studies have shown that higher infliximab trough levels are associated with favorable short-term and long-term therapeutic outcomes in inflammatory bowel disease. There is a need to determine which ...

Mostrando ítems 1-5 de 5

Buscar en DSpace

Búsqueda avanzada

Listar

Todo RICSMUR

Listar por tema "Gastrointestinal Agents/therapeutic use"

Listar por tema "Gastrointestinal Agents/therapeutic use"

Buscar en DSpace

Listar

Todo RICSMUR

Mi cuenta